…
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biostax Corp. (OTC Pink: BTAX) is a U.S.-listed microcap with sparse public disclosures and no clear description of core operations or revenue streams. Long-term growth drivers are not identifiable from available material; the company could benefit if it later reports credible operational, regulatory, or financial milestones that support reassessment.
Key risks are minimal disclosure, low liquidity tied to an OTC Pink listing and the attendant uncertainty that material operating or financial information may be unavailable to investors.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -2.36M | -3.54M | 3.59M | 1.59M | -3.40M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -2.36M | -3.54M | 3.59M | 1.59M | -3.40M |
| Selling general administrative | 0.96M | 1.15M | 0.59M | 0.76M | 2.50M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Reconciled depreciation | 0.05M | - | 0.00M | 0.00M | 0.00M |
| Ebit | -2.19M | -1.16M | -0.74M | -0.89M | -2.84M |
| Ebitda | -2.14M | - | - | - | - |
| Depreciation and amortization | 0.05M | - | - | - | - |
| Operating income | -1.48M | -1.16M | -0.74M | -0.89M | -2.84M |
| Other operating expenses | 1.48M | - | - | - | - |
| Interest expense | 0.17M | 0.12M | 0.21M | 0.48M | 0.89M |
| Net interest income | -0.17M | -0.12M | -0.21M | -0.65M | -0.89M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.48M | 1.16M | 0.74M | 0.89M | 2.84M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total other income expense net | -0.88M | -2.25M | 4.54M | 3.13M | 0.34M |
| Net income from continuing ops | -2.36M | -3.54M | 3.59M | 1.59M | -3.40M |
| Net income applicable to common shares | - | -3.54M | 3.59M | 1.59M | -3.40M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 0.04M | 0.96M | 3.14M | 0.01M | 0.01M |
| Intangible assets | 0.71M | 0.76M | - | - | - |
| Total liab | 4.56M | 3.48M | 11.09M | 11.68M | 13.69M |
| Total stockholder equity | -4.53M | -2.51M | -7.95M | -11.67M | -13.69M |
| Other current liab | 0.09M | 0.94M | 0.89M | 1.51M | 0.85M |
| Common stock | - | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -385.33M | -382.97M | -379.43M | -383.02M | -384.61M |
| Other assets | - | 0.05M | - | 0.00M | 0.00M |
| Cash | 0.03M | 0.15M | 0.49M | 0.01M | 0.00M |
| Total current liabilities | 4.56M | 3.48M | 11.09M | 11.68M | 13.69M |
| Net debt | 1.10M | 0.55M | 2.58M | 2.83M | 5.54M |
| Short long term debt | 1.13M | 0.70M | 3.07M | 2.84M | 5.55M |
| Other stockholder equity | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Property plant equipment | - | - | - | - | 0.00M |
| Total current assets | 0.03M | 0.15M | 3.14M | 0.01M | 0.00M |
| Net tangible assets | - | -3.28M | -7.95M | -11.67M | -13.69M |
| Short term investments | 0.00M | 0.00M | 2.65M | - | - |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 1.21M | 1.30M | 2.18M | 2.56M | 2.66M |
| Non current assets total | 0.01M | 0.81M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.00M | -0.50M | 0.00M | - | 0.00M |
| Change to liabilities | - | 0.39M | 0.10M | 0.10M | 0.89M |
| Total cashflows from investing activities | - | -0.50M | -0.50M | -0.50M | -0.50M |
| Net borrowings | 0.14M | 0.74M | 0.72M | 0.20M | 0.20M |
| Total cash from financing activities | 0.29M | 0.74M | 0.72M | 0.20M | 0.20M |
| Change to operating activities | - | 0.31M | 0.58M | 0.91M | 2.40M |
| Net income | -2.36M | -3.54M | 3.59M | 1.59M | -3.40M |
| Change in cash | -0.12M | -0.34M | 0.48M | 0.01M | -0.00M |
| Begin period cash flow | 0.15M | 0.49M | 0.01M | 0.00M | 0.01M |
| End period cash flow | 0.03M | 0.15M | 0.49M | 0.01M | 0.00M |
| Total cash from operating activities | -0.41M | -0.58M | -0.23M | -0.19M | -0.00M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.05M | - | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | - | - | 0.00M | 0.08M |
| Other cashflows from financing activities | 0.15M | - | - | - | - |
| Change to netincome | - | 2.25M | -4.54M | -2.96M | -0.20M |
| Capital expenditures | 0.00M | 0.50M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.85M | 0.70M | 0.68M | 1.01M | 3.35M |
| Other non cash items | 1.05M | -3.17M | 0.03M | -3.17M | 0.38M |
| Free cash flow | -0.41M | -1.08M | -0.23M | -0.19M | -0.00M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BTAX Biostax Corp. |
- -% |
0.00 | - | - | - | - | 268.58 | -16.41 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.
| Name | Title | Year Born |
|---|---|---|
| Ms. Noreen M. Griffin | Founder, Executive VP of Business Development & CEO | 1953 |
| Ms. Kelly O'Brien Wilson | President | 1971 |
| Mr. Glen A. Farmer M.B.A. | Chief Financial Officer | 1969 |
| Mr. Robert Wilson | VP of Strategy & Director | 1973 |
| Ms. Cynthia Douglas | Company Secretary | 1973 |
| Dr. Joseph M. Fortunak | Vice President of Global Research & Development and Chemical Development | 1955 |
| Ms. Kelly O'Brien Wilson | President | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.